Blood Screening Industry Overview

The global blood screening market size is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. 

• The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030.

Blood Screening Market Segmentation

Grand View Research has segmented global blood screening market report based on technology, product, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA & EIA )
• Next Generation Sequencing (NGS)
• Western Blotting (WB)

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent
• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • India
  • Japan
  • China
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Key Companies profiled:

• Abbott
• Danaher Corporation (Beckman Coulter)
• Becton Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Hoffman-La Roche Ltd.
• Grifols, S.A.
• Ortho-Clinical Diagnostics, Inc.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.
• SOFINA s.a (Biomerieux)

Key Blood Screening Company Insights

Some of the key companies in the market include Bio-Rad Laboratories, Inc., Hoffman-La Roche Ltd., Grifols, S.A., and others. These companies adopt strategies such as strategic collaborations to enhance innovation, mergers, and acquisitions to expand capabilities, and new product launches to address evolving healthcare needs, ensuring competitiveness and a strong market presence.

• Abbott manufactures specialized medical equipment that may utilize Blood Screening components for durability and lightweight properties. Beyond blood screening, Abbott operates in various segments, including laboratory diagnostics, cardiovascular devices, diabetes care, and nutrition products, thereby enhancing its portfolio and addressing diverse healthcare needs.
• Bio-Rad Laboratories, Inc. develops diagnostic instruments that may incorporate Blood Screening materials for enhanced performance and reliability in relation to Blood Screening. The company also engages in other segments, such as quality control products, gene expression analysis, and protein purification, positioning itself as a leader in both research and clinical settings.

Recent Developments

• In May 2023, Siemens Healthineers launched two new analyzers, the Atellica HEMA 570 and Atellica HEMA 580, designed for high-volume hematology testing, crucial for blood screening. These advanced devices can streamline the complete blood count (CBC) process, offering rapid results and improved workflow efficiency. With the ability to process up to 120 tests per hour, these analyzers can address the growing demand for timely diagnostics in critical care settings.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.